A Phase II Study of Alemtuzumab and Pentostatin In T-Cell Neoplasms.

Trial Profile

A Phase II Study of Alemtuzumab and Pentostatin In T-Cell Neoplasms.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Alemtuzumab; Pentostatin
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2010 Actual patient number (26) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Planned end date changed from 1 Feb 2011 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top